

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/22	A1	(11) International Publication Number: WO 97/34596 (43) International Publication Date: 25 September 1997 (25.09.97)
(21) International Application Number: PCT/IT97/00056 (22) International Filing Date: 12 March 1997 (12.03.97) (30) Priority Data: RM96A000171 15 March 1996 (15.03.96) IT (71) Applicant (for all designated States except US): MENDES S.R.L. [IT/IT]; Via Catania, 1, I-00161 Roma (IT). (72) Inventor; and (75) Inventor/Applicant (for US only): MORETTI, Sonia [IT/IT]; Via Gatteschi, 47, I-00162 Roma (IT). (74) Agents: CAVATTONI, Fabio et al.; Cavattoni - Raimondi, Viale dei Parioli, 160, I-00197 Roma (IT).		(81) Designated States: CA, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: USE OF AN ALKANOYL-L-CARNITINE FOR THE TREATMENT OF GLUTAMATE MEDIATED DISEASES		
(57) Abstract The use of an alkanoyl-L-carnitine, e.g. acetyl-L-carnitine, or a pharmacologically acceptable salt thereof is disclosed to produce a medicament for the therapeutic treatment or prophylaxis of glutamate-mediated cytological disturbances or diseases.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

USE OF AN ALKANOYL-L-CARNITINE FOR THE TREATMENT OF GLUTAMATE MEDIATED DISEASES

The present invention relates to a novel therapeutic use of an alkanoyl L-carnitine (as defined hereinbelow) or a pharmacologically acceptable salt thereof for the therapeutic treatment or prophylaxis of glutamate-mediated disturbances or diseases. More particularly, the present invention relates to the therapeutic treatment with an alkanoyl L-carnitine or a pharmacologically acceptable salt thereof of individuals in whom glutamate contributes towards the pathogenesis of a particular disease or gives rise to cytological disturbances, or alternatively to the prophylaxis of such diseases or disturbances.

Glutamate is a non-essential and glucogenic amino acid which is in equilibrium with α -ketoglutarate. It forms the amide, glutamine, by incorporating ammonia. By transamination, glutamine can give its amine group to various keto acids to form α -ketoglutaminate. The latter is then hydrolysed to α -ketoglutarate and ammonia by the action of a specific diaminase. The concentration of L-glutamate in peripheral blood ranges between 141 and 311 $\mu\text{mol/L}$. Increased extracellular concentrations of glutamate can competitively inhibit the membrane transport of cystine into the cell, with consequent oxidative damage. High levels of glutamate are present in many morbid conditions, as already demonstrated by White in 1952 (White J.M. et al., J. Clin. Lab. Med. 40:703, 1952). It is, however, emphasized that high levels of glutamate were observed in individuals with tumours in the digestive apparatus, bronchial carcinomas, malignant lymphomas, Hodgkin's disease and breast and ovary tumours (Beaton J.R. et al., Can. Med. Ass. J. 65:219, 1951). Recently, high levels of glutamate have also been found in the plasma of individuals with HIV (human immunodeficiency virus) infections (Droge W. et al., J. Cancer. Res. Clin. Oncol. 114:124, 1988). In the central nervous system, it has been demonstrated that high concentrations of glutamate contribute towards neuronal damage by excitotoxic mechanisms, following binding of glutamate to the

NMDA (N-methyl-D-aspartate) receptors, and on account of oxidative stress, following competition for the uptake of cystine by neurons (Dewhurst S. et al., Molecular Medicine Today 1:16, 1996).

From that which has been outlined above, it is evident that variations in the concentration or in the metabolism of glutamate can contribute towards the pathogenesis of many diseases or give rise to cytological disturbances. Examples of diseases or disturbances characterized by altered levels of glutamate include cancer, infection with HIV, immunodeficiencies, drug dependencies, headaches, chronic fatigue syndrome, schizophrenic disorders, epilepsy, amyotrophic lateral sclerosis and other motor neuron diseases and peripheral neuropathies, senile and presenile dementias, apoplexy and sequences thereof, cerebrovascular ischaemic diseases, decreased cerebral flow and altered cerebral metabolism, neurodegenerative diseases, Huntington's disease, Parkinson's disease, prion protein diseases, meningo-encephalitis, and Chinese restaurant syndrome.

The use of certain substances can also give rise to high levels of glutamate. Examples of such substances are cocaine and sulphuride.

According to the present invention, the administration of an alkanoyl L-carnitine wherein the alkanoyl group has 2-6 carbon atoms or a pharmacologically acceptable salt thereof can alleviate glutamate-mediated cytological disturbances.

Preferably, the alkanoyl L-carnitine is selected from the group comprising acetyl-, propionyl-, butyryl-, valeryl- and isovaleryl-L-carnitine.

In the description which follows, the expression pharmacologically acceptable salt of an alkanoyl L-carnitine is understood to refer to any salt of the latter with an acid which does not give rise to undesired toxic effects or side effects. These acids are well known to pharmacologists and to persons skilled in the pharmaceutical field.

Non-limiting examples of such salts are: chloride; bromide; iodide; aspartate, particularly hydrogen aspartate; citrate, particularly hydrogen citrate; tartrate; phosphate, particularly hydrogen phosphate; fumarate, particularly hydrogen fumarate; glycerophosphate, glucose phosphate; lactate; maleate, particularly hydrogen maleate; orotate; oxalate, particularly hydrogen oxalate; sulphate, particularly hydrogen sulphate; trichloroacetate, trifluoroacetate and methanesulphonate.

For the sake of simplicity and clarity, hereinbelow reference will be made to acetyl L-carnitine only, it being understood, however, that whatever disclosed and claimed in connection with acetyl L-carnitine equally applies to all of the above-identified alkanoyl L-carnitines and the pharmacologically acceptable salts thereof, which may be used alone or as a mixture thereof.

According to the present invention, 50 mg - 15 g per day, preferably 500 mg - 10 g per day, of alkanoyl L-carnitines or an equivalent amount of pharmacologically acceptable salts thereof are administered orally or parenterally for the treatment or prophylaxis of glutamate-mediated diseases or disturbances.

Also according to the present invention, alkanoyl L-carnitines or pharmacologically acceptable salts thereof can be administered in combination with cortisone medicaments, antioxidants, anti-inflammatory agents, immunomodulatory agents, cytostatic agents, immunological agents, endocrinological agents, vascular agents or vasodilators.

Still according to the present invention, a pharmaceutical composition is provided which can be administered orally or parenterally for the therapeutic treatment or prophylaxis of glutamate-mediated cytological disturbances or diseases, this composition comprising as active principle an amount of an alkanoyl L-carnitine, or pharmacologically acceptable salts thereof, which is effective for reducing the levels of

glutamate, and at least one pharmacologically acceptable excipient. The composition may also advantageously comprise the medicaments listed above.

Previous therapeutic uses of acetyl L-carnitine for the therapeutic treatment of myocardial arrhythmia and ischaemia, of functional peripheral vasculopathies of the arteries, of senile dementia and of peripheral neuropathies are already known.

For all the known therapeutic uses, the daily dose administered is from about 2 to about 20 mg of L-carnitine or an equivalent amount of a pharmacologically acceptable salt thereof/kg of body weight/day.

However, there is no correlation between the known therapeutic uses of acetyl L-carnitine mentioned above and that which constitutes the subject of the present invention.

It has now been found, surprisingly, that acetyl L-carnitine and analogues (despite the technical prejudice arising from the prior publications and patents) are capable of reducing the levels of glutamate in human biological fluids. It is emphasized by ample supporting scientific literature that the mechanism of action of acetyl L-carnitine was focused at the cerebral level, whereas, in the present invention, a loading action of the metabolism of glutamate is also demonstrated at the systemic level.

The examples which follow are intended to illustrate the invention and should not in any way be understood as limiting the scope thereof.

Example 1

Twelve individuals infected with HIV were enrolled. Blood was taken before and after oral treatment with acetyl L-carnitine at a dose of 3 g/day for 4 weeks. The glutamate was measured by a colorimetric method according to Beutler (Beutler O.H. et al., Methods of Enzymatic

Analysis Vol. IV, page 1708, 1974), and the results were expressed as L-glutamate per $\mu\text{mol/L}$.

Table 1

Patient	Before	After
#1	202	161
#2	169	153
#3	534	161
#4	518	250
#5	356	178
#6	348	161
#7	340	120
#8	138	50
#9	299	186
#10	194	153
#11	485	234
#12	299	81
AVERAGE	323.5000	157.3333
Standard deviation	135.2321	56.0298
Student test		0.0001

It is known that HIV-infected individuals can have varying levels of glutamate in the plasma. The experiments reported here demonstrated that the oral administration of acetyl L-carnitine reduces the levels of glutamate in the peripheral blood, independently of the fact that the patient might have normal or increased levels of glutamate in his or her blood.

Example 2

A female patient with a previous history of drug dependency, with chronic hepatopathy from hepatitis C virus, with HIV antibodies, who exhibited pronounced asthenia, lacking strength in the lower limbs

with paraesthesia and difficulty in walking diagnosed as "axial cerebellar and tetrapyramidal syndrome" and who, under magnetic resonance examination, exhibited an "enlargement of the supratentorial ventricular system, with predominance of the left lateral ventricle and moderate enlargement of the subarachnoid spaces as in atrophy with predominant subcortical expression" underwent a parenteral treatment with acetyl L-carnitine at a dose of 3 g/day for 4 weeks. Before and after the treatment, the glutamate in the plasma and in the cerebrospinal fluid was assayed.

The results demonstrated a reduction in the glutamate in the blood from 201 $\mu\text{mol/L}$ to 125 $\mu\text{mol/L}$ and in the fluid from 62 $\mu\text{mol/L}$ to 16 $\mu\text{mol/L}$.

This example confirms that treatment with acetyl L-carnitine can reduce the levels of glutamate in the cerebrospinal fluid and in the blood.

Claims

1. Use of an alkanoyl L-carnitine wherein the alkanoyl group has 2-6 carbon atoms or a pharmacologically acceptable salt thereof to produce a medicament for the therapeutic treatment or prophylaxis of glutamate-mediated cytological disturbances or diseases.
2. The use of claim 1, wherein the alkanoyl L-carnitine is selected from the group comprising acetyl-, propionyl-, butyryl-, valeryl- and isovaleryl-L-carnitine.
3. The use of claims 1 or 2, wherein the glutamate-mediated cytological disturbances or diseases are cancer, infection with HIV, immunodeficiencies, drug dependencies, headaches, chronic fatigue syndrome, schizophrenic disorders, epilepsy, amyotrophic lateral sclerosis and other motor neuron diseases and peripheral neuropathies, senile and presenile dementias, apoplexy and sequences thereof, cerebrovascular ischaemic diseases, decreased cerebral flow and altered cerebral metabolism, neurodegenerative diseases, Huntington's disease, Parkinson's disease, prion protein diseases, meningo-encephalitis, and Chinese restaurant syndrome
4. The use of claims 1, 2 or 3, wherein the alkanoyl L-carnitine or the pharmacologically acceptable salt thereof is administered in combination with cortisone medicaments, antioxidants, anti-inflammatory agents, immunomodulatory agents, cytostatic agents, immunological agents, endocrinological agents, vascular agents or vasodilators.
5. The use of any one of the preceding claims, which comprises the oral or parenteral administration of 50 mg - 15 g per day of the alkanoyl L-carnitine or an equivalent amount of the pharmacologically acceptable salt thereof.

6. The use of claim 5, which comprises the oral or parenteral administration of 500 mg - 10 g per day of the alkanoyl L-carnitine or an equivalent amount of the pharmacologically acceptable salt thereof.
7. The use of any one of the preceding claims, wherein the alkanoyl L-carnitine is acetyl L-carnitine.
8. An orally or parenterally administrable pharmaceutical composition for the therapeutic treatment or prophylaxis of glutamate-mediated cytological disturbances or diseases, which comprises as active principle an amount of an alkanoyl L-carnitine wherein the alkanoyl group has 2-6 carbon atoms, or a pharmacologically acceptable salt thereof, which is effective for reducing the levels of glutamate, and at least one pharmacologically acceptable excipient.
9. The pharmaceutical composition of claim 8, wherein the glutamate-mediated cytological disturbances or diseases are cancer, infection with HIV, immunodeficiencies, drug dependencies, headaches, chronic fatigue syndrome, schizophrenic disorders, epilepsy, amyotrophic lateral sclerosis and other motor neuron diseases and peripheral neuropathies, senile and presenile dementias, apoplexy and sequences thereof, cerebrovascular ischaemic diseases, decreased cerebral flow and altered cerebral metabolism, neurodegenerative diseases, Huntington's disease, Parkinson's disease, prion protein diseases, meningo-encephalitis, and Chinese restaurant syndrome.
10. The composition of claims 8 or 9, which further comprises cortisone medicaments, antioxidants, antiinflammatory agents, immunomodulatory agents, cytostatic agents, immunological agents, endocrinological agents, vascular agents or vasodilators.
11. The composition of any one of claims 8 to 10, which is suitable for the oral or parenteral administration of 50 mg - 15 g per day of active principle.

12. The composition of any one of claims 8 to 10, which is suitable for the oral or parenteral administration of 500 mg - 10 g per day of active principle.

INTERNATIONAL SEARCH REPORT

Inter nal Application No
PCT/IT 97/00056

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NEUROCHEM. RES., vol. 19, no. 7, 1994, pages 795-798, XP000676007 M. CASTORINA ET AL.: "Age-dependent loss of NMDA receptors in hippocampus, striatum and frontal cortex of the rat: prevention by acetyl-L-carnitine." * discussion *	1-3,7-9
X	EXP. GERONTOL., vol. 28, no. 6, 1993, pages 537-548, XP000675888 M. CASTORINA ET AL.: "A cluster analysis study of acetyl-L-carnitine effect on NMDA receptors in aging." see the whole document	1-3,7-9

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

20 June 1997

Date of mailing of the international search report

0 3. 07. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Klaver, T

INTERNATIONAL SEARCH REPORT

Int. Application No.
PCT/IT 97/00056

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 00137 A (BERNARDINI) 5 January 1995 see page 1 - page 4 ---	1-3,5-9, 11,12
X	EP 0 498 144 A (SIGMA-TAU) 12 August 1992 see the whole document ---	1-3,5-9, 11,12
X	EP 0 376 899 A (SIGMA-TAU) 4 July 1990 see page 5 -----	1-3,5-9, 11,12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/IT 97/00056

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9500137 A	05-01-95	AU 6922994 A CA 2142725 A WO 9500138 A	17-01-95 05-01-95 05-01-95
EP 498144 A	12-08-92	IT 1244636 B AT 119770 T DE 69201660 D DE 69201660 T ES 2070478 T IE 66025 B JP 4295424 A US 5192805 A	08-08-94 15-04-95 20-04-95 20-07-95 01-06-95 10-01-96 20-10-92 09-03-93
EP 376899 A	04-07-90	DE 68908145 T ES 2058596 T JP 2207020 A US 5043355 A	25-11-93 01-11-94 16-08-90 27-08-91